Autism Spectrum Disorder Treatment Market (By Type: Autistic Disorder, Asperger's Syndrome, Others; By Drug Class; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The global autism spectrum disorder (ASD) treatment market was surpassed at USD 1.88 billion in 2021 and is expected to hit around USD 3.5 billion by 2030, growing at a CAGR of 7.15% from 2022 to 2030.

Autism Spectrum Disorder Treatment Market Size 2021 to 2030

The autism spectrum disorder (ASD) treatment market is witnessing growth due to the rising burden of the disease. Recently, in March 2022, the updated report of the World Health Organization estimates about 1 in 100 children are suffering from ASD worldwide. According to an October 2021 article, the prevalence of ASD in the U.S. was 1.7% and 1.8% in children aged 4 and 8 years respectively. In addition, the prevalence in Europe ranged between 0.38% to 1.55%. Thus, the current evidence demonstrates the global increase in the prevalence of autism spectrum disorder over the past years.

Autism Spectrum Disorder treatment involves anticonvulsants, antipsychotics, antidepressants, and other drugs that treat symptoms of the disorder. However, currently, there are no treatment options for ASD in the market. Therefore, research and development for better treatment options are offering remunerative opportunities for market growth. For example, in May 2022, FDA granted fast-track designation to Curemark’s CM-AT indicated for ASD in 3-8 years old children. Moreover, in November 2021, Indian researchers developed the 6BIO compound, which has shown potential in improving daily activities in the pre-clinical investigation of patients with an autism spectrum disorder. 

Scope of The Report

Report Coverage Details
Market Size in 2021 USD 1.88 billion
Revenue Forecast by 2030 USD 3.5 billion
Growth rate from 2022 to 2030 CAGR of 7.15%
Base Year 2021
Forecast Period 2022 to 2030
Segmentation Type, Drug Class, Distribution Channel, Region
Companies Covered

Curemark LLC, Bristol-Myers Squibb, Merck & Co., Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, Otsuka Pharmaceutical, Yamo Pharmaceuticals, F. Hoffmann-La Roche Ltd., and Axial Therapeutics amongst others

 

The autism spectrum disorder market has been segmented based on drug class as follows:

  • Anti-convulsants
  • SSRIs
  • Anti-psychotics
  • Stimulants
  • Others 

Furthermore, the marketplace is witnessing strong public and private support through investments and funding for research and development. For instance, The Autism Impact Fund announced a capital investment in Yamo Pharmaceuticals, LLC to support phase 2 clinical studies of L1-79, indicated for ASD in November 2021. In addition, Axial Therapeutics successfully raised USD 37 million in Series C funding for AB-2004 drug candidates’ phase 2 clinical trials in children with autism in October 2021.

The space reported a significant impact of the COVID-19 pandemic which is accelerating the market growth. According to the “Coping with autism during lockdown period of the COVID-19 pandemic” published article, during the pandemic ASD patients witnessed accelerated behavioral issues and trouble in coping with mental well-being. 

Strategic initiatives such as partnerships, collaborations and investment by key market players are accelerating the market growth. For instance, in July 2022, Sangamo Therapeutics and Novartis AG announced a partnership for developing Zinc Finger technology targeting genes therapies for neurological disorders such as ASD. 

Key Players

  • Curemark LLC
  • Bristol-Myers Squibb
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Otsuka Pharmaceutical
  • Yamo Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Axial Therapeutics 
  • others

Market Segmentation

  • By Type
    • Autistic Disorder
    • Asperger's Syndrome
    • Others
  • By Drug Class
    • Anti-convulsants
    • SSRIs
    • Anti-psychotics
    • Stimulants
    • Others
  • By Distribution Channel
    • Hospital pharmacy
    • Retail pharmacy
    • Online pharmacy
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa (MEA)

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Autism Spectrum Disorder Treatment Market 

5.1. COVID-19 Landscape: Autism Spectrum Disorder Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Autism Spectrum Disorder Treatment Market, By Type

8.1. Autism Spectrum Disorder Treatment Market, by Type, 2022-2030

8.1.1 Autistic Disorder

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Asperger's Syndrome

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Autism Spectrum Disorder Treatment Market, By Drug

9.1. Autism Spectrum Disorder Treatment Market, by Drug, 2022-2030

9.1.1. Anti-convulsants

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. SSRIs

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Anti-psychotics

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Stimulants

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Autism Spectrum Disorder Treatment Market, By Distribution Channel 

10.1. Autism Spectrum Disorder Treatment Market, by Distribution Channel, 2022-2030

10.1.1. Hospital pharmacy

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Retail pharmacy

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Online pharmacy

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Autism Spectrum Disorder Treatment Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Drug (2017-2030)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Drug (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Drug (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Drug (2017-2030)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Drug (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Drug (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Drug (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Drug (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Drug (2017-2030)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Drug (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Drug (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Drug (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Drug (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Drug (2017-2030)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Drug (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Drug (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Drug (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Drug (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Drug (2017-2030)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Drug (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Drug (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 12. Company Profiles

12.1. Curemark LLC

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bristol-Myers Squibb

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merck & Co.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Novartis AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pfizer Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Eli Lilly and Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Johnson & Johnson

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Otsuka Pharmaceutical

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Yamo Pharmaceuticals

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. F. Hoffmann-La Roche Ltd.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers